特立妥单抗在既往接受BCMA靶向治疗后的复发/难治性多发性骨髓瘤患者中的疗效与安全性
MajestEC-1研究1/2期C队列纳入40例既往接受BCMA靶向治疗(抗体药物偶联物或CAR-T)的复发/难治性多发性骨髓瘤患者,接受皮下特立妥单抗1.5 mg/kg每周一次治疗。中位随访28.0个月,总缓解率52.5%,中位缓解持续时间14.8个月,中位无进展生存4.5个月,中位总生存15.5个月;感染发生28例(70.0%),其中5级感染4例(10%)。
要点
- 既往BCMA靶向治疗后R/RMM患者接受特立妥单抗总缓解率52.5%,≥完全缓解30.0%。
- 中位无进展生存4.5个月,中位总生存15.5个月,中位缓解持续时间14.8个月。
- 感染发生28例(70.0%),3/4级13例(32.5%),5级4例(10%)。
核心结论
- MajestEC-1试验C队列结果证明,特立妥单抗在既往接受过BCMA靶向治疗的重度经治R/RMM患者中具有良好的疗效和安全性。
研究设计与样本
- MajestEC-1为1/2期研究,C队列纳入40例既往接受BCMA靶向治疗(抗体药物偶联物或CAR-T)的R/RMM患者,接受皮下特立妥单抗1.5 mg/kg每周一次治疗。
主要发现
- 中位随访28.0个月(范围0.7-31.1),中位既往治疗线数6(范围3-14)。
- 既往BCMA靶向治疗包括抗体药物偶联物(n=29)、CAR-T(n=15)或两者兼有(n=4)。
- 总缓解率52.5%,47.5%达非常好的部分缓解及以上,30.0%达完全缓解及以上。
- 中位缓解持续时间14.8个月,中位无进展生存4.5个月,中位总生存15.5个月。
- 感染发生28例(70.0%),最大3/4级13例(32.5%),5级4例(10%)。
关键数值与推荐
- 最常见治疗中出现的不良事件为中性粒细胞减少、感染、细胞因子释放综合征和贫血;细胞减少和感染为最常见≥3级不良事件。
- 开始特立妥单抗前,基线BCMA表达和免疫特征未受既往抗BCMA治疗影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). In the phase 1/2 MajesTEC-1 study, a cohort of patients who had prior BCMA-targeted therapy (antibody-drug conjugate [ADC] or chimeric antigen receptor T-cell [CAR-T] therapy) was enrolled to explore teclistamab in patients previously exposed to anti-BCMA treatment. At a median follow-up of 28.0 months (range, 0.7-31.1), 40 patients with prior BCMA-targeted therapy had received subcutaneous 1.5 mg/kg weekly teclistamab. The median prior lines of treatment was 6 (range, 3-14). Prior anti-BCMA therapy included ADC (n = 29), CAR-T (n = 15), or both (n = 4). The overall response rate was 52.5%; 47.5% of patients achieved very good partial response or better, and 30.0% achieved complete response or better. The median duration of response was 14.8 months, the median progression-free survival was 4.5 months, and the median overall survival was 15.5 months. The most common treatment-emergent adverse events (TEAEs) were neutropenia, infections, cytokine release syndrome, and anemia; cytopenias and infections were the most common grade ≥3 TEAEs. Infections occurred in 28 patients (70.0%; maximum grade 3/4, n = 13 [32.5%]; grade 5, n = 4 [10%]). Before starting teclistamab, baseline BCMA expression and immune characteristics were unaffected by prior anti-BCMA treatment. The MajesTEC-1 trial cohort C results demonstrate favorable efficacy and safety of teclistamab in patients with heavily pretreated R/RMM and prior anti-BCMA treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03145181 and #NCT04557098.
引用
- Touzeau C, Krishnan AY, Moreau P, et al. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024. PMID: 39172760. doi:10.1182/blood.2023023616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。